Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
Published on 08/07/2025 at 18:07 | prnewswire.co.uk
Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumorsPreclinical data of DT-7012 position this Treg depleting anti-CCR8 antibody as a highly differentiated candidate for clinical development Preclinical findings demonstrate high potential of the PAR2 biased negative allosteric modulator (NAM) program to potentiate anti-tumor immunityView original content:https://www.prnewswire.co.uk/news-releases/domain-therapeutics-presents-novel-data-addressing-key-challenges-in-oncology-at-aacr-2025-302441519.html
en | boerse | 67948355 |
